Good MorningEquity markets rebounded last week but investors are cautioned not to read too much between the lines. The move was not supported by any kind of good news so is nothing more than a relief rally within the greater bear market. The news that did come out was not positive for the index as it all points to an overly aggressive Fed and the prospect of another 75 basis point interest rate hike at the FOMC meeting next week.
This week will be another challenge for the market. The CPI and retail sales data are due out and either could move the market. The takeaway is that weak CPI points to weakening economics and recession while a strong retail sales figure would support the idea of aggressive Fed action so the market may be in a no-win situation. Featured: 5 Stocks Poised to Soar Under Trump's Presidency (Ad) 
|
Markets | |
The Internet Security Stocks have been in a deep correction all year because of fears of slowing growth but still, there is no sign of that yet—results from Checkpoint Software (NASDAQ: CHKP) to SentinelOne, Inc. (NYSE: S) prove that demand for cyber security is not only still strong but acc... Read the Full Story |
|
|
Markets | | Video game publisher Electronics Arts (NYSE: EA) stock has been weathering the storm from the demand shock in the video gaming industry. Video games are a discretionary item and rising inflation is causing consumers to pullback on their discretionary spending. Clues to the weakness was indicated by ... Read the Full Story |
|
Markets | |
Auto stocks may be in favor again, as prices for used cars continue to plummet on excess supply. The auto market has been functioning at odds with economic laws recently, and at times prices of used cars have been higher than their new model counterpart. But as the money supply starts to tig... Read the Full Story |
|
From Our PartnersREVEALED: $194 Trillion Trump Market Pattern
Trump fires off a tweet and stocks tank…
He gives a speech and the markets soar…
Now, a new Trump executive order is set to set off a wave worth a potential $194 trillion in the markets.
And Wall Street insider Larry Benedict says it could hand investors who missed out on Trump’s first term a second chance. | | Click here to discover this exciting new trading pattern. |
|
Markets | | Discount retailer Dollar General (NYSE: DG) stock is up 5% for the year as it rides the recession wave higher. The Company operates over 18,300 small box discount stores across 47 states in the U.S. It sells mostly consumer staple items comprised of consumables, seasonal items, home products and app... Read the Full Story |
|
Politics | | Ukraine pressed its swift counteroffensive in the northeastern part of the country even as a nuclear plant in the Russia-occupied south completely shut down in a bid to prevent a radiation disaster as fighting raged in the area Read the Full Story |
|
From Our PartnersBehind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented.
And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots…
What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book. | | Claim your FREE copy of Crypto Revolution now. |
|
Markets | | Inflation isn’t only costing small businesses money. It’s costing them customers as well.
At the Bushwick Grind Cafe in Brooklyn, New York, Kymme Williams-Davis has raised prices and switched to different types of goods to keep up with the rising costs of milk, coffee, paper goods an... Read the Full Story |
|
Politics | | Payment processor Visa Inc. said Saturday that it plans to start separately categorizing sales at gun shops, a major win for gun control advocates who say it will help better track suspicious surges of gun sales that could be a prelude to a mass shooting.
But the decision by Visa, th... Read the Full Story |
|
Politics | | Payment processor Visa Inc. said late Saturday that it plans to start separately categorizing sales at gun shops, a major win for gun control advocates who say it will help better track suspicious surges of gun sales that could be a prelude to a mass shooting.
But the decision by Vis... Read the Full Story |
|
Markets | | Southern California welcomed cooler temperatures and spotty rain Saturday as a tropical storm veered off the Pacific Coast and faded, helping put an end to a blistering heat wave that nearly overwhelmed the state’s electrical grid Read the Full Story |
|
Markets | | The Consumer Price Index (CPI) is the inflation gauge. Inflation is the rate at which prices are rising and in turn eroding your buying power. It’s released by the U.S. Bureau of Labor Statistics (BLS) on a monthly basis. It measures the average rate of change in prices paid by consumers for a... Read the Full Story |
|
Monday's Early Bird Stock Of The Day Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey. | View Today's Stock Pick |
|